Blocking IL1RAP on cancer-associated fibroblasts in pancreatic ductal adenocarcinoma suppresses IL-1-induced neutrophil recruitment
Authors:
- Nils HansenNHNils Hansen
- Pablo Peña-MartínezPPPablo Peña-Martínez
- Petter SkoogPSPetter Skoog
- Katrin ReinbachKRKatrin Reinbach
- Finja C HansenFHFinja C Hansen
- Susanne Larsson FariaSFSusanne Larsson Faria
- Caitríona GrönbergCGCaitríona Grönberg
- Kawther AbdillehKAKawther Abdilleh
- Susanne MagnussonSMSusanne Magnusson
- Karin von WachenfeldtKWKarin von Wachenfeldt
- Camilla Rydberg MillrudCMCamilla Rydberg Millrud
- David LibergDLDavid Liberg
Open Access
- 18 December 2024
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 12 (12) , e009523
Abstract
Background Pancreatic ductal adenocarcinoma (PDAC) represents a major clinical challenge due to its tumor microenvironment, which exhibits immune-suppressive properties that facilitate cancer progression, metastasis, and therapy resistance. Interleukin 1 (IL-1) signaling has been implicated as a driver in this process. Mechanistically, both IL-1α and IL-1β bind to the IL-1 receptor type 1, forming a complex with IL-1-receptor accessory protein (IL1RAP), which triggers downstream signaling pathways. The IL1RAP blocking antibody nadunolimab is currently in clinical development, but the precise consequences of inhibiting IL-1 signaling in PDAC remains elusive. Methods To evaluate the biological relevance of blocking IL1RAP using nadunolimab in a PDAC animal model, human PDAC cells and cancer-associated fibroblasts (CAFs) were co-transplanted into mice. To study the underlying mechanisms of IL1RAP blockade ex vivo, co-cultured PDAC cells and CAFs were treated with nadunolimab prior to RNA sequencing. Migration assays were performed to assess how nadunolimab affects interactions between CAFs and myeloid immune cells. Finally, to establish a clinical correlation between IL1RAP expression and nadunolimab treatment effects, we analyzed tumor biopsies from a clinical phase I/II study in which nadunolimab was administered to patients. Results In the xenograft mouse model, nadunolimab exhibited antitumor effects only when human CAFs were co-transplanted with PDAC cells. IL-1 stimulation induced CAFs to secrete chemokines that recruited neutrophils and monocytes. The secretion of this chemokine and the migration of myeloid cells were inhibited by nadunolimab. Media conditioned by IL-1-stimulated CAFs sustained a neutrophil population with a tissue invasion phenotype, an effect that was reversed by nadunolimab. In a cohort of metastatic late-stage PDAC patients receiving nadunolimab as monotherapy, high IL1RAP expression in tumors was associated with extended progression-free survival. Conclusions Our study demonstrates that targeting IL1RAP on CAFs inhibits IL-1-induced chemokine secretion and recruitment of neutrophils and monocytes, thereby counteracting the immunosuppressive microenvironment in PDAC. These findings highlight the therapeutic potential of targeting IL1RAP in PDAC.Keywords
Funding Information
- Cancerfonden (22 2158 Pj)
- Governmental funding of clinical research within the NHS (2024-0067)
- Cantargia AB (N/A)
- Swedish Research Council (2023-01806)
- Medical Faculty of Lund University (N/A)
This publication has 49 references indexed in Scilit:
- IL-1β+ macrophages fuel pathogenic inflammation in pancreatic cancerNature, 2023
- Blockade of IL-1α and IL-1β signaling by the anti-IL1RAP antibody nadunolimab (CAN04) mediates synergistic anti-tumor efficacy with chemotherapyCancer Immunology, Immunotherapy, 2022
- CCL2-mediated monocytes regulate immune checkpoint blockade resistance in pancreatic cancerInternational Immunopharmacology, 2022
- First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumoursBritish Journal of Cancer, 2021
- CCL2 produced by pancreatic ductal adenocarcinoma is essential for the accumulation and activation of monocytic myeloid‐derived suppressor cellsImmunity, Inflammation and Disease, 2021
- Integrated Genomic Characterization of Pancreatic Ductal AdenocarcinomaCancer Cell, 2017
- Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinomaBritish Journal of Surgery, 2016
- The Genotype-Tissue Expression (GTEx) projectNature Genetics, 2013
- Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancerBritish Journal of Cancer, 2013
- A critical role for interleukin‐1 receptor accessory protein in interleukin‐1 signalingEuropean Journal of Immunology, 1997